Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Cisco who wrote (630)	12/10/1997 12:46:00 AM
From: Cisco	Read Replies (3) \| Respond to of 1894

Interesting comment on the conference call on Yahoo: messages.yahoo.com@m2.yahoo.com Cisco

To: Cisco who wrote (630)	12/10/1997 11:31:00 AM
From: Frank Buck	Respond to of 1894

Cisco, I called and got tired of playing the telephone game. The bottom line is that I left my number with Encore (the company that runs the recording-service) to call me back. As of yet they have not. No matter because this morning I purchased a few more K of ACMI shares in anticipation of the "expected-renewed" interest in the company. Great news regarding Gombrich also envisioning fewer players in this sector. As we have previously discussed I believe NPTH is a candidate for a substantial drop in share price. They have been continuosly drifting down and because of their inability to read the ThinPrep (CYTC's) monolayer preps, I believe they-NPTH will fall further. The Mystery Man (Yahoo ACMI poster) made some valid points. The first was about AccuMed's previous PR firm. How can we (shareholders) "PAY" someone that informs the Company not to communicate with us? YIKES!The second is that the molecularbiology division is receiving some impressive orders which in and by themselves might put us where analyst estimates are for the quarter. The Cytopathology division which is "starting" to receive some domestic as well as international signed contracts can be the "icing-on-the-cake. The first quarter looks like it will see a lot of "pushing" by AccuMed for closure of cyto-sales initiated in the previous quarters. The Detroit Lab evaluation I am sure has been instrumental in allowing the sales-force to make their closing statements. The additional first quarter road shows you depict will also be beneficial along with the March '98 Medical Conference presentation regarding the efficacy of the AcCell System. FDA approval for the updated system? Is that the AcCell 3000 (the next generation cyto-system)? I am wondering when the AcCell Savant System will be nearing FDA approval consideration and what that means to the Company in terms of expected revenues. I am so glad that the AcCell System is able to interphase with the CYTC ThinPrep System. I wonder why AccuMed informed George at the Boston meeting that they (AccuMed) really weren't pushing for a marriage of the two. It is nice to have all bets covered. Look at NPTH and then look at CYTC share-prices. They appear to be a mirror image of one another. CYTC-up and NPTH-down. Don't forget that NeoPath is still sitting on a chunk of change that is much larger than our cash position. With some impressive sales and some streamlining of operations perhaps AccuMed should be able to narrow the gap in the next couple of quarters. Thanks Mystery Man for pushing to have better communications between the Company and the investment community. Frank